This company has been marked as potentially delisted and may not be actively trading. Jounce Therapeutics (JNCE) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock JNCE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Philly Nonprofit Jounce Partners Helps Teachers Unlock Their Students’ Full PotentialFebruary 17, 2025 | msn.comTaboola Partners with Jounce Media to Verify Ad Inventory is Free From Made for Advertising (MFA) PropertiesOctober 2, 2024 | markets.businessinsider.comSan Diego VC, OrbiMed make competing buyout offers for struggling TheseusNovember 27, 2023 | bizjournals.comJounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply SourceSeptember 19, 2023 | tmcnet.comKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce MediaSeptember 18, 2023 | finance.yahoo.comMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce MediaSeptember 5, 2023 | tmcnet.comBoard Member at Jounce Therapeutics Exercises Options Worth $324KMay 5, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $172KMay 4, 2023 | benzinga.comJounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock OptionsMay 4, 2023 | benzinga.comJounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock OptionsMay 4, 2023 | benzinga.comJounce Therapeutics (Nasdaq:JNCE) HeadlineTrading was temporarily halted for "JNCE" at 07:05 PM with a stated reason of "News pending."...May 4, 2023 | marketbeat.comJounce Therapeutics Announces Closing of Tender OfferMay 3, 2023 | finance.yahoo.comJounce Therapeutics (NASDAQ:JNCE) Now Covered by StockNews.comApril 30, 2023 | marketbeat.comJNCE Jounce Therapeutics, Inc.April 29, 2023 | seekingalpha.comThe past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitableApril 17, 2023 | finance.yahoo.comWhat is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?March 29, 2023 | benzinga.comBuyout Offer Sends Jounce Jumping 20%March 27, 2023 | msn.comJounce Therapeutics Shares Rally on Buyout Deal >JNCEMarch 27, 2023 | marketwatch.comJounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCEMarch 27, 2023 | marketwatch.comJounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobsMarch 27, 2023 | finance.yahoo.comJounce Therapeutics (Nasdaq:JNCE) HeadlineTrading was temporarily halted for "JNCE" at 08:03 AM with a stated reason of "News pending."...March 27, 2023 | marketbeat.comMoore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law FirmMarch 23, 2023 | benzinga.comTang Capital Partners Now Owns 10.2% of Jounce TherapeuticsMarch 17, 2023 | 247wallst.comJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerMarch 16, 2023 | finance.yahoo.comJounce (JNCE) Up 41% on Buyout Offer From Concentra BiosciencesMarch 16, 2023 | finance.yahoo.com10% Owner of Jounce Therapeutics Makes $85K BuyMarch 15, 2023 | benzinga.comWhy Jounce Therapeutics Stock Is Moving Higher Today?March 15, 2023 | finance.yahoo.comConcentra Biosciences Proposes To Acquire Jounce Therapeutics - Quick FactsMarch 15, 2023 | markets.businessinsider.comTang Capital Partners Now Owns 10.20% of Jounce Therapeutics (JNCE)March 15, 2023 | msn.comJounce Therapeutics Jumps Premarket on Buyout Bid >JNCEMarch 15, 2023 | marketwatch.comWhy Is Jounce Therapeutics (JNCE) Stock Up 37% Today?March 15, 2023 | investorplace.comJounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesMarch 14, 2023 | finance.yahoo.comJounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating accountMarch 13, 2023 | finance.yahoo.comJounce Therapeutics Full Year 2022 Earnings: Beats ExpectationsMarch 11, 2023 | finance.yahoo.comMoore Kuehn Encourages ROCC, JNCE, BRMK, and FOCS Investors to Contact Law FirmMarch 1, 2023 | benzinga.comJOUNCE THERAPEUTICS INVESTOR ALERT by the Former...March 1, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Jounce Therapeutics, Inc. MergerFebruary 23, 2023 | benzinga.comCambridge biotech Jounce to cut staff, merge with U.K. drug developerFebruary 23, 2023 | finance.yahoo.comJounce Therapeutics, Inc.: Redx and Jounce Announce Recommended Business CombinationFebruary 23, 2023 | finanznachrichten.deJounce Shares Bounce Higher on Tie-Up With Redx >JNCEFebruary 23, 2023 | marketwatch.comRaymond James downgrades Jounce Therapeutics (JNCE) to a HoldFebruary 23, 2023 | markets.businessinsider.comJounce stock soars ~35% on all-stock merger with Redx PharmaFebruary 23, 2023 | msn.comRedx and Jounce Announce Recommended Business CombinationFebruary 23, 2023 | finance.yahoo.comJounce Therapeutics Shares Up 12% After Hours On Layoff PlansFebruary 22, 2023 | marketwatch.comJounce Therapeutics Announces RestructuringFebruary 22, 2023 | finance.yahoo.comShort Interest in Jounce Therapeutics, Inc. (NASDAQ:JNCE) Declines By 46.3%January 27, 2023 | marketbeat.comCowen Financial Products LLC Ups Stake in Jounce Therapeutics Inc (JNCE)January 25, 2023 | nasdaq.comJounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Sold by Trv Gp II LLCJanuary 20, 2023 | marketbeat.comAssenagon Asset Management S.A. Sells 571,100 Shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE)January 13, 2023 | marketbeat.comJNCE.O - | Stock Price & Latest News | ReutersJanuary 12, 2023 | reuters.com Get Jounce Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JNCE Media Mentions By Week JNCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JNCE News Sentiment▼0.001.12▲Average Medical News Sentiment JNCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JNCE Articles This Week▼00▲JNCE Articles Average Week Get the Latest News and Ratings for JNCE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Jounce Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies IKT News PLX News CVM News ZIVO News IZTC News CRTX News ALVR News AIM News NKGN News CLDI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JNCE) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAmerica Betrayed Porter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jounce Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JNCE Stock Alerts